PERL-Fenofibrate Study

Fenofibrate: Preventing Kidney Function Loss

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

The purpose of this study is to learn more about the effect of a drug called fenofibrate on kidney function in people with type 1 diabetes. A few studies have suggested that fenofibrate may slow loss of kidney function in people with type 2 diabetes. However, it has not been given to people specifically with type 1 diabetes mellitus to reduce their chances to develop kidney disease. The information gathered in the present study will be used to design a larger study to see whether fenofibrate can be used to prevent kidney function loss also in people with type1 diabetes.

This study involves

• 8 study visits over 1 ½ years
• Take 1 fenofibrate pill or inactive pill daily
• Comprehensive kidney function exams at 4 of the study visits
• Blood and urine tests
• EKG

All study related procedures are provided at no charge.
Monetary compensation and parking validation will be provided for eligible study participants.

Recruitment:

• Age 18-70
• Diagnosed with type 1 diabetes
• Have had diabetes for at least 8 years
• We determine that you have signs of kidney problems due to diabetes